Prepared for: Ada Health CEO Date: March 11, 2026 Analyst: Ada Cockpit Research Team
2025 Revenue
$17.3B
+4% YoY
Adjusted EBITDA
$5.3B
+12% YoY
Net Income
$3.4B
+19.3% YoY
Free Cash Flow
$2.4B
+16% YoY
Net Debt
$13.3B
-$1.2B vs 2024
Market Cap
$36.7B
Mar 10, 2026
2025 Revenue Mix by Segment
Revenue Growth Trajectory (2023-2026E)
Executive Summary
Company Overview: Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a global pharmaceutical company headquartered in Tel Aviv, Israel, founded May 1, 1935. The company employs 33,950 people globally (December 31, 2025).
Strategic Position: Executing "Pivot to Growth" strategy (launched May 2023), transforming into a balanced innovative and generics biopharmaceutical leader. Delivered three consecutive years of growth with innovative medicines reaching $3.1B (+35% YoY) in 2025.
Forward-Looking Disclaimer: This report contains forward-looking statements based on current expectations as of March 2026. Actual results may differ materially due to risks including competitive pressures, patent expirations, regulatory uncertainties, pipeline execution risk, and debt obligations.
Key Financial Metrics (FY 2025)
Metric
2025 Actual
2024 Actual
Change
Revenue
$17.3 billion
$16.5 billion
+4% YoY
Adjusted EBITDA
$5.3 billion
$4.7 billion
+12% YoY
Net Income
$3.4 billion
$2.85 billion
+19.3% YoY
Free Cash Flow
$2.4 billion
$2.1 billion
+16% YoY
Net Debt
$13.3 billion
$14.5 billion
-$1.2B
Innovative Medicines Portfolio (2025)
Product
Indication(s)
2025 Revenue
YoY Growth
Patent/Exclusivity
Austedo / Austedo XR
Tardive dyskinesia; Huntington's chorea
$2.26B
+34%
US: 2031-2041
Ajovy
Migraine prevention
$673M
+30%
US: ~2035
Uzedy
Schizophrenia; Bipolar I
$191M
+63%
US: 2042
Copaxone
Multiple sclerosis
~$400-500M
Declining
Patents expired
Ada Patient Finder Analysis: Top Opportunities
1. Austedo for Tardive Dyskinesia (Fit Score: 9/10)
Metric
Value
Addressable Undiagnosed Pool (US)
100,000 - 200,000 patients
Net Revenue per Patient
$12,000 - $54,000 annually
Underdiagnosis Rate
60% of TD cases undiagnosed
Diagnostic Delay
80% experience multi-year delays
Ada Symptom Surfacing
Excellent - involuntary movements observable
Pitch Hook: Tardive dyskinesia affects 500,000-800,000 Americans, yet 60% remain undiagnosed. Ada Patient Finder can identify individuals reporting involuntary facial movements—classic TD symptoms often missed—and navigate them to specialists for evaluation and potential Austedo treatment.
2. Ajovy for Migraine Prevention (Fit Score: 7/10)
Metric
Value
Addressable Pool (US)
5 - 8 million patients
Net Revenue per Patient
$5,500 - $9,000 annually
Underdiagnosis Rate
50% never seek medical care
Ada Symptom Surfacing
High - classic migraine patterns surfaceable
R&D Pipeline Highlights
Program
Indication
Phase
Expected Milestone
Olanzapine LAI
Schizophrenia
Phase 3
FDA approval 2026
Duvakitug
UC & Crohn's
Phase 3
Ongoing enrollment
TEV-'408
Vitiligo
Late-stage
Data 2026
2026-2027 Outlook
Metric
2026 Guidance
2027 Target
Revenue
$16.4 - 16.8B
Low-single digit growth
Adjusted EBITDA
$5.0 - 5.3B
N/A
Operating Margin
N/A
30%
Free Cash Flow
$2.0 - 2.4B
>$2.7B
Net Leverage
N/A
2x debt-to-EBITDA
References
This report cites 97 sources across financial filings, earnings releases, FDA databases, market research, clinical trials, and industry publications. Key sources include: